

Join the American College of Medical Toxicology (ACMT) at the **2024 North American Congress of Clinical Toxicology (NACCT)** in Denver, Colorado, from September 19-23, 2024. The **ACMT Pre-Meeting** on **Thursday, September 19th** will explore the fascinating topic of **EntheoTox: Navigating the Psychedelic Frontier**.

In recent years, there has been a resurgence of interest in the therapeutic potential of psychedelics, accompanied by a growing need to understand their safety profiles. This full-day symposium will bring together experts from diverse fields to explore the intersection of psychedelics and toxicology, shedding light on the physiological, psychological, and toxicological aspects of these compounds. Keynote speakers include:

- Charles Grob, MD, a pioneer in the research of psilocybin and psychiatry. Dr. Grob's groundbreaking
 work has paved the way for understanding the therapeutic potential of psychedelics in mental health
 treatment.
- Jim Grigsby, PhD, known for his groundbreaking work in cognitive neuroscience and neuropsychology, Dr. Grigsby will be speaking on the neurobiology of psychedelics.

Other sessions will feature such topics as the use of psychedelics during pregnancy or breastfeeding, pharmaceutical preparation of fungi, the safety of microdosing and its efficacy, the use of psychedelics in palliative care, the ethical considerations of indigenous rights in psychedelic science, and much, much more!

Learning Objectives

- 1. Explore the potential therapeutic applications of psychedelics while considering the safety parameters and risk-benefit profiles associated with various therapeutic modalities.
- 2. Discuss strategies for mitigating potential risk and adverse effects associated with psychedelic use, with an emphasis on harm reduction and responsible exploration.
- 3. Enhance understanding of the pharmacology and toxicology of psychedelics.
- Examine the ethics of broad adoption of traditional medicines, and the impact this has on Indigenous communities.
- 5. Evaluate the challenges and considerations surrounding FDA approval of psychedelic medications.